Jeremy Bender, Day One Biopharmaceuticals CEO

Day One Bio­phar­ma­ceu­ti­cals inks re­search col­lab­o­ra­tion with Swedish biotech

Day One Bio­phar­ma­ceu­ti­cals se­cured a re­search and li­cens­ing deal with Sprint Bio­science in a bid to build out its can­cer-fight­ing ar­se­nal.

The Bay Area biotech is pay­ing $3 mil­lion up­front for the glob­al rights of one of Sprint’s can­cer pro­grams known as VA­DA, which is de­signed to tar­get the pro­tein known as vac­cinia-re­lat­ed ki­nase 1 or VRK1, which is preva­lent in kid­ney, liv­er and pan­cre­at­ic can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.